Genes Encoding Tumor-Specific Antigens Are Expressed in Human Myeloma Cells

Genes of the MAGE, BAGE, GAGE, and LAGE-1/NY-ESO-1families encode antigenic peptides that are presented by HLA class I molecules and that are recognized on human tumors by autologous cytolytic T lymphocytes. These genes are expressed in many solid tumor types but not in normal tissues, except male g...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1999-08, Vol.94 (4), p.1156-1164
Main Authors: van Baren, Nicolas, Brasseur, Francis, Godelaine, Danièle, Hames, Gérald, Ferrant, Augustin, Lehmann, Frédéric, André, Marc, Ravoet, Christophe, Doyen, Chantal, Spagnoli, Giulio C., Bakkus, Marleen, Thielemans, Kris, Boon, Thierry
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antigen Presentation
Antigens, Neoplasm - genetics
Antigens, Neoplasm - immunology
Biological and medical sciences
Cytotoxicity, Immunologic
Female
Gene Expression Regulation, Neoplastic - immunology
Histocompatibility Antigens Class I - immunology
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunohistochemistry
Immunopathology
Male
Medical sciences
Middle Aged
Multiple Myeloma - genetics
Multiple Myeloma - immunology
T-Lymphocytes, Cytotoxic - immunology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Genes of the MAGE, BAGE, GAGE, and LAGE-1/NY-ESO-1families encode antigenic peptides that are presented by HLA class I molecules and that are recognized on human tumors by autologous cytolytic T lymphocytes. These genes are expressed in many solid tumor types but not in normal tissues, except male germline cells. Because the latter cells are devoid of HLA molecules, the derived antigens are strictly tumor-specific and should constitute safe immunogens for cancer immunotherapy. We detected a significant expression of these genes in a high proportion of bone marrow samples from patients with advanced multiple myeloma. This observation provides a basis for clinical trials aimed at inducing a cellular immune response directed at malignant plasma cells in advanced myeloma patients.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V94.4.1156